Ozempic^® 2.0 mg Approved in the US for the Treatment of Type 2 Diabetes

Novo Nordisk announced that the FDA has approved a 2.0 mg dose of Ozempic® a glucagon-like peptide-1 analogue for the treatment of adults with type 2 diabetes.